Nature's Sunshine (NATR) Q2 2026 Earnings Call Transcript
Nature's Sunshine Products (NATR) reported Q2 2026 net sales of $117.0 million (+2%, or +4% excluding FX), gross margin of 73.7%, GAAP net income of $3.5 million ($0.19/share), and adjusted EBITDA of $11.3 million. Full-year 2026 sales guidance was cut to $490-$500 million and adjusted EBITDA to $48-$52 million. China sales fell 20% while Japan rose 50%.
How this was made
The 30-second read
Why it matters
The most tradable update is the FY2026 guidance reduction tied to China operational issues and exchange-rate changes, alongside continued investment spending and a planned 2027 North America direct-selling reinvigoration.
Market read
Guidance cut and China weakness are likely to drive estimate revisions, while digital and subscription metrics provide a counter-narrative for longer-duration investors.
What to watch
Operating cash flow deterioration and higher inventory levels could constrain near-term execution, and the Vision for Growth plan depends on ramping SG&A and reinvigorating North America direct selling in 2027.
Background
The transcript covers Nature's Sunshine Products Q2 2026 results and management's Vision for Growth strategy, including guidance changes and regional performance commentary.
Ticker impact
Nature's Sunshine lowered full-year 2026 sales guidance to $490M-$500M and adjusted EBITDA to $48M-$52M on China slowdown and FX changes.
Likely bearish bias for near-term estimates and sentiment, with potential stabilization if investors focus on digital growth and margin initiatives.
The article provides explicit guidance ranges and cites the drivers (China operational issues, FX slowdown) while also highlighting growth pockets (Japan, North America digital, autoship LTV).
Market effects
Direct-selling and wellness peers may face renewed scrutiny on China exposure and FX sensitivity, but the digital channel narrative could support the broader theme.
China weakness is a specific regional drag, while Japan strength and Eastern Europe growth may temper regional risk appetite.
Limited spillover beyond small-cap consumer wellness, unless investors generalize the China and FX drivers to similar business models.
Counterpoint
Investors may look past the China decline by emphasizing North America digital growth and autoship/social commerce acceleration, which could offset the guidance reset over time.
Key entities
- companyNature's Sunshine Products
US-listed wellness and direct-selling company reporting Q2 2026 results and lowering FY2026 guidance.
- executiveKen Romanzi
CEO who set the $1B revenue target and discussed Vision for Growth and M&A approach.
- executiveJon Lanoy
Chief Accounting Officer who flagged China weakness and SG&A expectations for 2026.
- executiveRuth Perkins
Appointed Chief Financial Officer effective Sept. 1, 2026.
